Updated:
Scipher Medicine
Scipher Medicine uses a 300,000-patient registry and AI to match autoimmune patients to effective therapies, led by CEO Reginald Seeto.
Scipher Medicine
Scipher Medicine was co-founded by Drs. Joseph Loscalzo and Albert-László Barabási, and built on two decades of research that mapped 89% of all protein interactions in human cells. The firm uses this map to determine why specific targeted therapies work for some patients and fail for others in immunology. Based in Waltham, Massachusetts, its platform represents a convergence of network biology and AI trained on a proprietary clinico-genomic registry. The company operates across three business lines: therapy selection via biomarker tests, drug development and commercialization, and data-driven discovery. Its flagship product, PrismRA, predicts response to anti-TNF therapies in rheumatoid arthritis patients and has Medicare coverage. Pharmaceutical partnerships are central to the model. In inflammatory bowel disease, Scipher collaborates with Galapagos; a multi-target partnership with Ionis points to drug-target discovery. The geographic footprint is primarily US-focused, with clinical data drawn from a national patient base. Funding has progressed through Series D, with notable strategic investors including UnitedHealth Group. The board includes representatives from Khosla Ventures, Northpond Ventures, Blue Owl, and aMoon — a mix of venture and growth-stage investment perspectives. Courtney Morris leads business development, signaling the firm's push to embed its tests within health systems and pharma workflows. Scipher launched PRoBeNet, a biomarker discovery network, to systematically expand its platform beyond rheumatoid arthritis into new autoimmune indications. What sets Scipher apart structurally is its dual-facing model. It sells a clinical diagnostic test directly into the healthcare ecosystem while simultaneously monetizing the same underlying data and network biology platform to large pharmaceutical partners for drug R&D. This hybrid model migrates value in both directions — clinical utility on one side, discovery and commercial IP on the other — creating a differentiated revenue architecture in precision medicine.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
Reginald Seeto
President & Chief Executive Officer
Ryan Phan
Chief Operating Officer
Courtney Morris
Chief Business Officer
Dina Ghiassian
SVP, Network Medical and Data Science
Sector focus
Frequently asked questions
What is Scipher Medicine's core technology platform?
The platform combines a protein interaction map covering 89% of human cellular proteins with one of the largest molecular data registries in autoimmune disease. AI algorithms then analyze this data to identify biomarkers that predict individual patient response to specific targeted therapies. This approach underlies both its clinical test, PrismRA, and its pharmaceutical discovery partnerships.
Is Scipher Medicine a diagnostic company or a drug developer?
It operates as both. The company commercializes a Medicare-covered diagnostic test to guide therapy selection in rheumatoid arthritis while also licensing drug targets and partnering with pharmaceutical companies on drug development. This dual model allows it to generate near-term clinical revenue and longer-term royalty or milestone income from drug discovery.
Who are Scipher Medicine's key pharmaceutical partners?
Publicly disclosed partners include Galapagos, with whom Scipher signed a collaboration in inflammatory bowel disease that ultimately led to Galapagos in-licensing novel drug targets. Ionis Pharmaceuticals also signed a multi-target partnership focused on applying the network biology platform to discover new therapeutic targets.
What is the clinical utility of the PrismRA test?
PrismRA is a molecular signature test that predicts whether a rheumatoid arthritis patient will respond to anti-TNF therapies, which are a major class of biologic drugs. It has published clinical utility studies and gained Medicare coverage, allowing providers to make an informed treatment choice before starting a patient on a drug that may not work.
How is Scipher Medicine's board composed?
The board combines venture capital and growth equity representation with scientific founders. Members include Samir Kaul of Khosla Ventures, Steve Liapis of Northpond Ventures, Todd Sone of aMoon, Timothy Anderson of Blue Owl, and founders Albert-László Barabási and Joseph Loscalzo, who hold faculty positions at Harvard, Northeastern, and Brigham and Women’s Hospital.
What real-world data does Scipher Medicine have access to?
Its data bank includes molecular samples from autoimmune patients and clinical data on over 300,000 patients across multiple autoimmune disease states. This registry underpins the biomarker discovery, drug response predictions, and pharmaceutical insights the company sells to partners.
How did UnitedHealth Group get involved with Scipher Medicine?
UnitedHealth Group invested in Scipher during a prior funding round, signaling payer-level interest in a diagnostic that can reduce spending on ineffective biologic drugs. A payer being an investor aligns commercial incentives between test adoption and systemic healthcare cost reduction.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: